In this Issue
- MindMed Tops Up Healthy Cash Balance with $75M Raise; Eyes Adding Depression to Pipeline?
- atai Approaches Phase 2 for DMT and R-MDMA Candidates
- Compass’ Phase 3 Program Generally On-Track, Potential for Slight Delay on Readout
- European Psychiatrists Remain Open to Psychedelics, Research
- Other Stories, including: Cybin’s Phase 3 plans; AbbVie’s $8.7bn neuropsych acquisition; Otsuka’s DTx pricing; Intra-Cellular Therapies’ preferred non-hallucinogenic lingo; Gilgamesh’s Fierce 15 spot; Incannex’s green light from FDA; and more.
***
MindMed Tops Up Healthy Cash Balance with $75M Raise; Eyes Adding Depression to Pipeline?
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue